AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies
Year: 2014
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Eytan M. Stein, Jessica K Altman, Robert Collins, Daniel J DeAngelo, Amir T Fathi, Ian Flinn, Arthur Frankel, Ross L Levine, Bruno C Medeiros, Manish Patel, Daniel A Pollyea, Gail J. Roboz, Richard M Stone, Ronan T Swords, Martin S. Tallman, Sam Agresta, Bin Fan, Hua Yang, Katharine Yen, Stéphane de Botton
Institutions: Memorial Sloan Kettering Cancer Center, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, The University of Texas Southwestern Medical Center, Dana-Farber Cancer Institute, Harvard University, Massachusetts General Hospital, Sarah Cannon, Stanford University, University of Colorado Cancer Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine, University of Miami, University of Miami Hospital, Sylvester Comprehensive Cancer Center, Agios Pharmaceuticals (United States), Institut Gustave Roussy
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W344909292